Company: BOLT
Filing Date: 2025-04-15
Form Type: DEF 14A
Source: 0000950170-25-054294
Chunk: 57

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-15
Form: DEF 14A
Chunk 57
---
 stock options  |      |     | Number of      
 securities     
 remaining      
 available for  
 issuance under 
 equity         
 compensation   
 plans          
 (excluding     
 securities     
 reflected      
 in column a)   |           |
|:------------------------------|:----|:----------------------|-----------:|:----|:---------------|-----:|:----|:---------------|----------:|
| Equity compensation plans     
 approved by stockholders (1)  |     |                       | 11,423,193 |     | $              | 2.50 |     |                | 2,609,694 |
| Equity compensation plans not 
 approved by stockholders      |     |                       |          — |     |                |    — |     |                |         — |
| Total                         |     |                       | 11,423,193 |     | $              | 2.50 |     |                | 2,609,694 |

(1) The equity compensation plans approved by security holders are described in Note 10 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024.

<div align='center'>36

CERTAIN RELATIONSHIPS AND RELATED PARTYTRANSACTIONS</div>

Related Person Transaction Policy and Procedures

Our Board adopted a related person transaction policy setting forth the policies and procedures for the identification, review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and a related person were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness and guarantees of indebtedness. In reviewing and approving any such transactions, our audit committee will consider all relevant facts and circumstances as appropriate, such as the purpose of the transaction, the availability of other sources of comparable products or services, whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction, management’s recommendation with respect to the proposed related person transaction and the extent of the related person’s interest in the transaction.

Certain Related Person Transactions

The following is a summary of transactions since January 1, 2023, to which we have been a participant in which the amount involved exceeded or will exceed $120,000, and in